5 Vogelstein B, Lane D, Levine A J. Surfing the p53 network. Nature, 2000, 408: 307-310？？
[2]
6 Oliner J D, Kinzler K W, Meltzer P S, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature,1992, 6381: 80-83
[3]
7 Vogelstein B, Kinzler K W. p53 function and dysfunction. Cell, 1992, 4: 523-526
[4]
8 Bond G L, Hu W, Levine A J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets, 2005, 5: 3-8？？
[5]
9 Oliner J D, Pietenpol J A, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature,1993, 362: 857-860？？
[6]
11 Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res, 1998, 26: 3453-3459？？
[7]
12 Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 2003, 13: 49-58？？
[8]
13 Espinoza-Fonseca L M. Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer. Theor Biol Med Model, 2005, 2: 1-6？？
[9]
14 Fry D C, Graves B, Vassilev L T. Development of E3-substrate (MDM2-p53) binding inhibitors: Structural aspects. Methods Enzymol,2005, 399: 622-633？？
[10]
15 Fry D C, Vassilev L T. Targeting protein-protein interactions for cancer therapy. J Mol Med, 2005, 83: 955-963？？
[11]
16 Cao C, Shinohara E T, Subhawong T K, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther, 2006, 5: 411-417
[12]
17 Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther, 2006, 5: 2358-2365？？
[13]
18 Jiang M, Pabla N, Murphy R F, et al. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem, 2007, 282: 2636-2645
[14]
19 Carvajal D, Tovar C, Yang H, et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res, 2005, 65: 1918-1924？？
[15]
20 Harris S L, Levine A J. The p53 pathway: Positive and negative feedback loops. Oncogene, 2005, 24: 2899-2908？？
[16]
1 Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74-108
[17]
2 Paredes L A, Blanco G C, Echenique E M, et al. Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer. Arch Bronconeumol, 2007, 43: 479-484
[18]
3 S？renson S, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol, 2001,40: 327-339
[19]
4 Lowe S W, Cepero E, Evan G. Intrinsic tumour suppression. Nature, 2004, 432: 307-315？？
[20]
10 Freedman D A, Wu L, Levine A J. Functions of the MDM2 oncoprotein. Cell Mol Life Sci, 1999, 55: 96-107？？
[21]
21 Iliakis G, Wang Y, Guan J, et al. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene, 2003, 22: 5834-5847？？
[22]
22 Dworakowska D, Gózdz S, Jassem E, et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer, 2002, 35: 35-41？？
[23]
23 Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res, 2008, 14: 5318-5324？？
[24]
24 Patel S, Player M R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs,2008, 17: 1865-1882？？
